【摘要】 目的探讨E2F1和p16INK4α在胃肠道间质瘤(gastrointestinal stromal tumors,GISTs)中的表达及两者的相关性,为GISTs的临床治疗和预后判断提供新的病理学依据。方法应用免疫组化EnVision法检测52例GISTs中p16INK4α和E2F1的表达情况,分析二者表达与Fletcher分级、进行性疾病(progressive disease,PD)及CD117和PKC-θ表达之间的关系,并对二者与GISTs预后的关系进行统计学分析。结果E2F1蛋白阳性率73.1%,与Fletcher分级呈显著正相关(P<0.001);E2F1阳性表达与CD117阳性表达之间有显著性差别(P<0.05);E2F1阳性细胞数大于75%的病例与小于75%的三组(<10%,10%-50%,50%-75%)之间PD发生率有显著性差异(P<0.05)。p16INK4α在52例GISTs中均有不同程度的阳性表达,与Fletcher分级呈显著负相关(P<0.001);p16INK4α阳性细胞数小于50%的病例与大于50%的两组(50%-75%,>75%)PD发生率之间差异有显著性(P<0.05)。结论E2F1、p16INK4α表达与GISTs预后有关,可作为GISTs预后的标记物。更多还原

【Abstract】 Objective To investigate the expression of E2F1 and p16INK4α in gastrointestinal stromal tumors(GISTs),and to provide a new pathological evidence for evaluating clinical treatment and prognosis. Methods EnVision immunohistochemical method was used to detect the expression of E2F1 and p16INK4α in 52 cases of GISTs,and to analyze their relationship with Fletcher grading,progressive disease(PD),expression of CD117 and PKC-θ,and prognosis of GISTs.Results E2F1 expression was positively related to Fletcher grading of GISTs (P<0.001).The positive expression rate of E2F1 was 73.1%,and it was significantly different with CD117 positive expression(P<0.05).PD incidence in E2F1 expression>75% was higher than in E2F1 expression<75%(<10%,10%-50%,50%-75%,P<0.05).p16INK4α protein expressed in different degree among 52 cases of GISTs,and the expression was negatively related to Fletcher grading of GISTs(P<0.001).PD incidence in p16INK4α expression<50% was higher than in p16INK4α expression>50%(50%-75%,>75%,P<0.05). Conclusion The expression of E2F1 and p16INK4α are closely related with the prognosis of GISTs,and may be considered as molecular markers for prognosis of GISTs.更多还原